Targeted NIF-hirulog hybrid (Chongqing Fujin Biomedical)
重组白细胞抑制因子和水蛭肽嵌合蛋白（重庆富进生物）
Report date: 2022/07/15 15:12:28
Base Information
Drug NameTargeted NIF-hirulog hybrid (Chongqing Fujin Biomedical)
Drug Alias Name
Classification
Mechanisms of Action
Targets
Therapy Area/Indications
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/Territory
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaPending
Originator CompaniesChongqing Fujin Biological Medicine Co Ltd
China Registration ClassClass 1 therapeutic biologic in China
Develop Information
Active CompaniesN/A
Inactive CompaniesChongqing Fujin Biological Medicine Co Ltd
Active IndicationsN/A
Inactive Indications
Other Information
ATC CodeN/A
Related LinksN/A